The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Weekly Current Affairs One-Liners Current Affairs 2026 plays a very important role in competitive examinations…
World Tourism Day is marked every year on September 27, and in 2026, the theme…
On Saturday, September 26, 2026, India further cemented its medal winning streak at the Asian…
India beat Iran in the men’s kabaddi finals of the 2026 Asian Games in Aichi-Nagoya,…
According to the Indian Ports Act, 2025, four ports have been declared as mega ports…
The Central Government has renewed the application of Armed Forces (Special Powers) Act, 1958 (AFSPA)…